Inventiva S.A. (IVA.PA)

4.18 €

+0.01 (+0.36%)
Rating:
Recommendation:
-
Symbol IVA.PA
Price 4.18 €
Beta 1.302
Volume Avg. 0.06M
Market Cap 176.121M
Shares () -
52 Week Range 3.5-12.7
1y Target Est -
DCF Unlevered IVA.PA DCF ->
DCF Levered IVA.PA LDCF ->
ROE -41.16% Strong Sell
ROA -35.28% Strong Sell
Operating Margin -
Debt / Equity 55.45% Buy
P/E -3.30 Strong Sell
P/B 2.32 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Frederic Cren
Healthcare
Biotechnology
Paris

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.